Holen Sie sich die Stockscreener-App
373.46
4.03%
14.46
Handel nachbörslich:
373.46
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$359.00
Offen:
$360
24-Stunden-Volumen:
730.61K
Relative Volume:
2.08
Marktkapitalisierung:
$8.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-14.87
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+10.46%
1M Leistung:
+18.39%
6M Leistung:
+6.18%
1J Leistung:
+53.28%
1-Tages-Spanne:
$357.76
$375.06
1-Wochen-Bereich:
$333.24
$375.06
52-Wochen-Spanne:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
373.46 | 8.00B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals director sells $16.6m in stock - Investing.com
Madrigal Pharmaceuticals director Taub sells $16.5 million in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan - MSN
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - simplywall.st
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
Piper Sandler reiterates Overweight rating on Madrigal stock amid strong launch - Investing.com Canada
MDGL: UBS Raises Price Target Amidst Steady Buy Ratings | MDGL S - GuruFocus
Madrigal Pharmaceuticals to Present at Canaccord Genuity Growth Conference - MSN
Jefferies raises Madrigal Pharmaceuticals stock price target to $502 on patent extension - Investing.com Canada
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Party Time: Brokers Just Made Major Increases To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Earnings Forecasts - uk.finance.yahoo.com
Leading vs lagging indicators on Madrigal Pharmaceuticals Inc. performanceSwing Trade Watchlist with Entry Zones - Newser
What to do if you’re stuck in Madrigal Pharmaceuticals Inc.Trade Ideas Based on Fundamental Metrics - Newser
Madrigal Pharmaceuticals Q2 2025 Earnings Preview - MSN
What to expect from Madrigal Pharmaceuticals Inc. in the next 30 daysFree Consistent Income Focused Trade List - Newser
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals: Strategic Growth and Market Potential Driven by Rezdiffra’s Success and Key Acquisitions - TipRanks
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript - Insider Monkey
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045 - MSN
MDGL Analyst Rating Update: Canaccord Genuity Raises Price Targe - GuruFocus
Cautious Outlook on Madrigal Pharmaceuticals: Sell Rating Amid Competitive Pressures and Valuation Concerns - TipRanks
Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus
Madrigal Pharmaceuticals shares fall 1.15% premarket after reporting a Q2 net loss of $42.3 million. - AInvest
Madrigal 2025 Q2 Earnings Strong Revenue Surge, Narrowed Losses - AInvest
Madrigal: Q2 Earnings Snapshot - New Haven Register
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com
Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest
Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest
Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool
Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha
Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News
Madrigal Pharmaceuticals reports Q2 EPS ($1.90), consensus ($3.53) - TipRanks
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial R - GuruFocus
Madrigal Pharmaceuticals Q2 Financial Results Exceed ExpectationsNews and Statistics - IndexBox
Madrigal Pharmaceuticals Q2 Net Loss Narrows, Revenue Increases; Shares Rise - MarketScreener
Madrigal Pharma's Q2 sales surge on Rezdiffra demand - MarketScreener
Madrigal Pharmaceuticals' Q2 2025 Earnings Signal a Pivotal Moment for Long-Term Value Creation - AInvest
Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $212.8M, vs. FactSet Est of $162.0M - MarketScreener
Madrigal Pharmaceuticals Reports $212.8 Million in Second-Quarter 2025 Net Sales for Rezdiffra™, Secures New Patent and Licensing Agreement - Quiver Quantitative
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
China momentum continues with Madrigal-CSPC, Arrowhead- Sanofi tie-ups: Deals Report - BioCentury
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):